Article: Endocare Expands Agreement to Distribute 15-Minute PSA Test to Urologists; Expands Existing OEM Agreement With Qualigen Physician Office Lab System.

IRVINE, Calif., Oct. 8 /PRNewswire/ --

Endocare, Inc. (Nasdaq: ENDO), a developer of innovative temperature-based treatments for prostate cancer and prostate obstruction, today announced that it entered into a new expanded distribution agreement with privately held Carlsbad, CA-based Qualigen, Inc. Under the new agreement, the Endocare sales force will now sell Qualigen's FDA-cleared, 15-minute total prostate specific antigen (Total PSA) test as a stand-alone product, non-exclusively directly to urology practices. The test, which provides rapid, fully-automated, laboratory quality PSA test results in physician office laboratories, eliminates patient anxiety that ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!